Acasti Pharma Inc

Change company Symbol lookup

Select an option...

ACST Acasti Pharma Inc

STBX Starbox Group Holdings Ltd

ANCFX American Funds Fundamental Investors® Class A

DFS Discover Financial Services

EJH E-Home Household Service Holdings Ltd

PYXS Pyxis Oncology Inc

FLGC Flora Growth Corp

BAOS Baosheng Media Group Holdings Ltd

CETY Clean Energy Technologies Inc

UEC Uranium Energy Corp

Go

Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.